Kornimate/medical-research-clean huggingface dataset:
a phase i/ii study to determine the maximum tolerated dose (mtd) and safety of cc-4047 (pomalidomide) administered in conjunction with cisplatin and etoposide

Conditions: Carcinoma, Small Cell

Summary: the purpose of this study is to determine the maximum tolerated dose and safety of cc-4047 (pomalidomide) given in combination with cisplatin and etoposide in patients with extensive disease small cell lung cancer.


Eligibility criteria:
inclusion criteria: * signature of informed consent * age \>= 18 * histologically or cytologically confirmed small cell lung cancer (sclc) * extensive stage sclc * eastern cooperative oncology group (ecog) performance status 0, 1 or 2 * brain metastases that are asymptomatic and do not require steroid control * females of child bearing potential must use two forms of birth control exclusion criteria: * pregnant or lactating females * prior use of cytotoxic chemotherapy * surgery within 14 days of study * radiation within 14 days of study * prior therapy with cc-4047 (pomalidomide), lenalidomide or thalidomide * concurrent use or anticipated use of anti-cancer agents * absolute neutrophil count (anc) \< 1500/mm\^3 * platelets \< 100 x 10\^3/µl * serum creatinine \>2.5 mg/dl * serum glutamic oxaloacetic transaminase (sgot) or serum glutamic pyruvic transaminase (sgpt) \> 3.0 x upper limit of normal (uln) * serum total bilirubin \> 1.8 mg/dl * uncontrolled hypercalcemia * creatinine clearance \<50 ml/min * uncontrolled hypertension * neuropathy \>= grade 2 * body mass index (bmi) \>= 40 * any other active invasive malignancy requiring treatment * known chronic infection with human immunodeficiency virus (hiv), hepatitis b virus (hbv) or hepatitis c virus (hcv) * inability or unwillingness to comply with birth control requirements
fursultiamine in esophageal squamous cell carcinoma patients who receive concurrent chemoradiotherapy

Conditions: Cancer Stem Cell

Summary: esophageal cancer is a common and fatal malignancy. it is the eighth most common incident cancer and the sixth leading cause of cancer death in the world. in taiwan, esophageal cancer was newly diagnosed in 2199 patients and was the cause of 1507 deaths in 2011. squamous cell carcinoma is the predominant histological tumor type, accounting for about 90% of the cases. esophageal squamous cell carcinoma (escc) is an aggressive disease, characterized with extensive local growth and frequent metastases. concurrent chemoradiotherapy (ccrt) with or without surgery is the treatment option for locally advanced escc. further, target therapy is used in conjunction with ccrt and surgery in escc since several years ago. however, the therapeutic outcomes are not satisfactory due to the emergence of chemo-radioresistance. it is imperative to investigate new biomarkers and to find novel treatment targets in escc. a small population of tumor-initiating cells or cancer stem cells (cscs) possess some biological functions like normal stem cells, including self-renewal, asymmetric cell division, slowly proliferation rate and drug-resistance. cscs from many primary tumors and cell lines express specific stem cell markers, including oct4, sox2, nanog, cd133 (promimin-1), nestin, cd44 ,cd24, aldh (aldehyde dehydrogenase) and c-kit. there are many evidences that cscs are responsible for tumor initiation, progression and metastasis. cscs are also believed to have important roles in cancer recurrence due to their resistance to anti-cancer drugs and radiation. cscs express high levels of atp-binding cassette (abc) transporters. abc transporter can pump cytotoxic drugs out of cells and is one important mechanism of multidrug resistance in cscs. in addition, cscs have high reactive oxygen species (ros) scavenger expression to remove ros produced from irradiation therapy. fursultiamine (also known as thiamine tetrahydrofurfuryl disulfide, ttfd) is a derivative of vitamin b and currently used for nutrition supplement. the investigators have identified that fursultiamine suppressed oct-4, sox-2, nanog expression and decreased abcb1 and abcg2 in tumor sphere of escc cell lines. in this project, the investigators will conduct a prospective phase ii study to investigate the effect of fursultiamine combined with ccrt in escc patients. stem cell markers in clinical specimens collected before and after ccrt will be evaluated.


Eligibility criteria:
inclusion criteria: * newly diagnosed stage ii and iii esophageal squamous cell carcinoma exclusion criteria: * ecog≧2; * impaired function of lung, liver, kidney or bone marrow
early cancer detection test - lung cancer china

Conditions: Lung Cancer

Summary: lung cancer is the most common cancer in china from both incidence and mortality rate point of view, with significantly lower 5-year survival rate than average. early detection is the recognized solution. ldct is more and more popular accepted as an effective screening methodology but leads to numerous indeterminate pulmonary nodules for physicians to distinguish too. the value of autoantibody test in risk assessing of ipns as well as early detection of lung cancer in high risk population has been demonstrated in clinical practice and trial but mainly in caucasian. purpose of this study is to understand the sensitivity, specificity and accuracy of candidate autoantibodies, and consequently explore the autoantibody combination with best clinical performance in chinese population.


Eligibility criteria:
inclusion criteria: * male or female aged 18 or above. * individuals complying with either of the following 1. diagnosed as lung cancer (histopathologically confirmed); 2. diagnosed as benign pulmonary nodule (confirmed by pathology or by follow-up based on 2018 chinese consensus on pulmonary nodule diagnosis and treatment); 3. without pulmonary nodule but with lung cancer risk factor, age \& gender matched recruited lung cancer patients. * participant is willing and able to provide necessary information required in crf. * participant is willing and able to give informed consent for participation in the study. exclusion criteria: * history of any cancer; * lung cancer patient who received or is receiving any treatment, including but not limited to surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy.

Keywords: tumor autoantibody early detection indeterminate pulmonary nodule
video tool to promote knowledge of syphilis as facilitator of hiv transmission

Conditions: Syphilis

Summary: during the winter of 2007, the syphilis advisory group and bureau of std control of the nyc department of health funded the emergency department of jacobi medical center to further evaluate the effectiveness of the syphilis and men video in additional settings where men access std related information and testing and where high-risk groups, such as msm, frequent. the video was evaluated for promoting knowledge of syphilis, especially as facilitator of hiv transmission, and in encouraging concurrent testing (syphilis and hiv) among men recruited from a community-based organization, an ambulatory care setting, and a dance club.

the solomon-four group design was applied to assess the effectiveness of the video in raising syphilis knowledge among participants, while controlling for the influence of the pre-test knowledge survey in skewing post-knowledge survey scores. participants in group 1 received a pre-test survey, the video intervention, and the post-test survey; group 2 received the pre-test and post-test surveys; group 3 received the video intervention and post-test survey; and group 4 received the post-test survey only. a computer-generated randomization list was used to assign participants to one of the four groups.

Eligibility criteria:
inclusion criteria: * must speak english or spanish exclusion criteria: * excluded if hearing or visually impaired

Keywords: syphilis video education knowledge black hispanic
a telephone intervention to improve participation in a screening program.

Conditions: Colorectal Cancer; Colorectal Neoplasms

Summary: objective: to assess the effectiveness of a brief telephone intervention added to an post invitation letter in the participation rate to a colorectal cancer screening program. methods: randomized controlled trial. this study is framed inside the colorectal cancer screening program of catalonia, concretely in the region of vallès occidental. this program is directed to men and women from 50 to 69 years. the screening test used is the fecal immunological test (fit) that is offered every 2 years. if the screening test is positive, a colonoscopy with sedation is offered as a diagnostic test.


Eligibility criteria:
inclusion criteria: * women and men from 50 to 69 years living in the selected territories (terrassa c, terrassa a, cerdanyola del vallès 1) that will be invited for the first time in the colorectal cancer screening program. exclusion criteria: * the same as those used in the population program: 1. history of colorectal cancer; 2. history of inflammatory bowel disease; 3. history of colorectal adenomas; 4. family history of polyposis syndromes or hereditary nonpolyposis colorectal cancer; 5. family history of colorectal cancer if: two first grade relatives affected or only one fist grade relative affected diagnosed before the age of 60; 6. terminal illness or severe disability which contraindicates the study of the colon. people is excluded temporally if: * 1) they have a colonoscopy performed in the last 5 years; * 2) present digestive signs or symptoms (rectal bleeding, change in bowel habits, abdominal pain, weight loss with fatigue and anorexia, abdominal mass); * 3) they express the will to be out of the program.

Keywords: screening early detection participation
functional yogurt consumption and its effects on the lipid profile of healthy subjects

Conditions: Cardiovascular Diseases; Apolipoproteins; Food Preferences; Low-density-lipoprotein-type; HDL; Triglycerides; Functional Food

Summary: the purpose of this study was to assess the effect of the daily intake of yogurts enhanced with sacha inchi oil and hybrid palm tree oil on human plasma lipids related to cardiovascular risk factors

after being recruited and signing a written informed consent about the study and potential risks, the participants were randomized and assigned in a double-blind manner to one of three intervention groups (control yogurt, sacha inchi oil yogurt, or hybrid palm tree oil yogurt; consumption 1 bottle of 200ml per day for 90 days.

Eligibility criteria:
inclusion criteria: * normal total cholesterol (≤200mg/dl) levels * have a yogurt consumption habit of at least three times a week * maximum level of moderate physical activity * body mass index (bmi) of ≤29.9kg/m2 * serum triacylglycerols below 400mg/dl exclusion criteria: * presence of chronic disease (arterial hypertension, diabetes mellitus, among others) * a history of illicit drug use and/or chronic alcohol use, active smoking * a well-established allergy to red palm olein and/or milk and its derivatives * consumption of nutritional supplements (antioxidants, omega 3, fiber, phytosterols) * pregnancy or lactation * having menopause * high consumption of nuts, flaxseed, chia, and sesame seeds

Keywords: pufa cardiovascular risk lipid profile healthy volunteers yogurt sacha inchi oil interspecific hybrid palm oil
chronic rhinosinusitis: biochemical markers and biofilm

Conditions: Chronic Rhinosinusitis

Summary: the investigators will conduct a descriptive, prospective, three-armed study concerning the pathophysiology of chronic rhinosinusitis. in one part of the study the investigators want to investigate the presence of biofilm in patients with chronic rhinosinusitis both with and without nasal polyps compared with a control group of subjects without chronic rhinosinusitis. the investigators will also compare quality of life in the three groups and correlate disease severity in biofilm patients versus patients where biofilm was not present. the hypothesis here is that biofilm patients suffers a more severe disease. in the other arm of the study the investigators will compare the presence of different biochemical compounds in the three study groups. the investigators specifically want to investigate matrix metalloproteases and apoptosis-inhibitors with immunohistochemistry. the investigators may also add other compounds to our test-battery if interesting candidates surface in the literature during the inclusion period. the purpose of this part of the study is to investigate candidates for the development of nasal polyposis. the investigators plan to include 100 patients suffering from chronic rhinosinusitis with nasal polyps, and 100 patients with chronic rhinosinusitis without nasal polyps and 30 control subjects.


Eligibility criteria:
inclusion criteria: * diagnosis of chronic rhinosinusitis based on epos3 * submitted to surgery * using nasal corticosteroids exclusion criteria: * age below 18 years * using antibiotics at the time of surgery * using systemic corticosteroids * sempers triad
efficacy and safety of fecal microbiota transplantation

Conditions: Fecal Microbiota Transplantation

Summary: in recent years, researches illustrate that multifactorial diseases such as functional gastrointestinal disorders, autoimmune diseases, metabolic, behavioral and neurological diseases are associated with an abnormal microbiome structure-dysbiosis, which means the imbalance of the microbiome community. fecal microbiota transplantation (fmt), the infusion of faeces from a healthy donor to the gastrointestinal tract of a recipient patient aiming to alter the intestine microbiota, is recommended to be performed in clostridium difficile infection(cdi) as the most effective therapy. it also being used experimentally in the treatment of the disease states linked to dysbiosis of the intestinal microbiota. however, the efficacy and safety of fmt to treat the dysbiosis-associated diseases is still in its infancy. to further verify the indications above, more data is required to be collected through studies.


Eligibility criteria:
inclusion criteria: confirmed diagnosis of any of following diseases: * irritable bowel syndrome * ulcerative colitis * crohn's disease * constipation * clostridium difficile infection * functional dyspepsia * parkinson's disease * metabolic syndrome * non-alcoholic fatty liver disease * autism spectrum disorder * radiation enteritis * atopic dermatitis * food allergic * graft-versus-host disease * obesity * diabetes mellitus * multi-drug resistant infection * hepatic encephalopathy * enteric dysbacteriosis * multiple sclerosis * pseudomembranous enteritis * acute pancreatitis * chronic fatigue syndrome * acute-on-chronic liver failure with hbv infection * alcoholic liver disease * anorexia * decompensated cirrhosis * henoch-schonlein purpura * autoimmune liver disease * systemic lupus erythematosus * rheumatoid arthritis * igg4-related disease * celiac disease * protein-losing enteropathy * asperger syndrome * rheumatoid arthritis * psoriasis * ankylosing spondylitis * immune checkpoint inhibition-related colitis * autoimmune enteropathy * drug-induced diarrhea * suffering from gastrointestinal symptoms such as constipation, diarrheas, abdominal pain, flatulence, etc. * the participants must be able to tolerate the fmt infusion method such as endoscopy, colonoscopy, capsule, nasoduodenal tube insertion, etc. exclusion criteria: * current pregnancy or breast-feeding; * suffering from other severe diseases, including liver or kidney failure, heart failure, mods, coma, cerebrovascular accident; * known contraindication to all fmt infusion method such as nasoduodenal tube insertion, endoscopy, colonoscopy and enema; * any conditions that may render the efficacy of fmt or at the discretion of the investigators.
first rtms for treatment of drug induced tardive syndromes. double randomized clinical trial

Conditions: Drug Induced Tardive Syndrome (DITS)

Summary: this study aims to evaluate the efficacy of rtms on dits. twenty patients with dits were recruited from the outpatient clinic of aswan university hospital. the patients were classified into two equal groups, 1st group received real high frequency rtms at 100% rmt and the 2nd group received sham stimulation with the same pulse delivery but with the coil placed perpendicular to the scalp. for each patient 10 sessions were administered once per day for 5 consecutive days each week for two weeks. all patients were assessed before rtms and immediately after the end of the 10 sessions. this study is double blinded (the doctor and the patients). assessment with aims scale and different parameters of cortical excitability were performed before and after the end of sessions treatment.

the aim of this study was to evaluate the efficacy of repetitive transcranial magnetic stimulation (rtms) on drug induced tardive syndromes. the effect of rtms compare. twenty patients with drug induced tardive syndromes were recruited from the outpatient clinic of aswan university hospital. the patients were classified into two equal groups, 1st group received real 20 hz-rtms at 100% rmt (a total of 2000 pulses to each hand area consisting of 10 trains of 200 pulses with intertrain interval 30 s), and the 2nd group received sham stimulation with the same pulse delivery as the 1st group but with the coil placed perpendicular to the scalp. for each patient 10 sessions were administered once per day for 5 consecutive days each week for two weeks. all patients were assessed before rtms and immediately after the end of the 10 sessions. the patients did not know which type of stimulation they received and to ensure that, the study was double blinded the doctor who assessed the patients didn't know which type of stimulation the patients received. none of the patients had had rtms before and were unaware of the type of stimulation.the aims scale and different parameters of cortical excitability were assessed before and after the end of session treatment.

Eligibility criteria:
inclusion criteria: * all patients with the spectrum of tardive dyskinesia (td) according to the diagnostic and statistical manual of mental disorders, fourth edition (dsm iv) exclusion criteria: * none of the patients suffered from any other clinically relevant disorders. * we exclude any patient with pacemaker or metallic devices * patients with history of epilepsy or metabolic diseases.

Keywords: rtms, drug induced tardive syndrome
sit-to-stand with feedback in sci patients

Conditions: Injuries, Spinal Cord

Summary: * does the utility of external feedback in terms of goal-directed lll approach during sts training immediately improve functional ability relating to walking in ambulatory patients with sci? * does the utility of lll feedback improve functional ability relating to walking in ambulatory patients with sci after 2-week training?

* to compare immediate effects of sts training with and without lll feedback on functional ability relating to walking in ambulatory patients with sci * to compare 2 weeks effects of sts training with and without lll feedback on functional ability relating to walking in ambulatory patients with sci.

Eligibility criteria:
inclusion criteria: * ambulatory spinal cord injury patients exclusion criteria: * deformity of musculoskeletal system

Keywords: feedback
a preliminary study to explore clinical endpoints in patients (male) with diarrhea-predominant irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: the purpose of this study is to explore and examine endpoints that allow evaluation of the "clinically significant improvements, focusing on the patient's chief complaint and the severity of major ibs symptoms" by this drug in patients with diarrhea-predominant irritable bowel syndrome (ibs).


Eligibility criteria:
inclusion criteria: * patients meeting the rome iii diagnostic criteria * loose (mushy) or watery stools within the last 3 months exclusion criteria: * patients having hyperthyroidism or hypothyroidism

Keywords: diarrhea ibs colonic diseases ym060
role of regulatory b cells in behçet's disease

Conditions: Behcet Disease

Summary: there are limited data about the role of regulatory b cells in behcet disease. in this study we aimed to identify the proportions of total b lymphocytes and their regulatory subset in different behcet disease phenotype and therapies concentrating on the cardiovascular system attempting to unravel their function in behcet disease.

behçet's disease is a chronic multi-organ vasculitis characterized by recurrent oral and genital aphthae, skin lesions, widespread thrombosis and aneurysmal formation, and serious involvement of the eyes and central nervous system. the innate and adaptive immune cells integrate in the pathogenesis of behçet's disease. interestingly, the gene expression analysis of behçet's disease patients and healthy controls revealed the modulation of a range of genes involved in biological processes in behçet's disease such as inflammation, apoptosis, angiogenesis, blood coagulation, vascular damage, signalling pathways, and immune responses, particularly, in innate immune cells, th17 cells and b cells. yet, the regulatory role of b cells in behçet's disease has not been thoroughly investigated. therefore, the aim of the current study is to identify the proportions of total b lymphocytes and their regulatory subset in different behçet's disease phenotypes and therapies attempting to unravel their function in behcet disease. the role of b cells and regulatory b cells in the cardiovascular system affection in behcet disease was studied in more details.

Eligibility criteria:
inclusion criteria: * thirty five adult patients who fulfilled the diagnostic criteria of behcet disease, and 39 age and sex matched healthy subjects as control exclusion criteria: * patients younger than 18 years old and those who were affected by other rheumatic disease other than behcet disease.
the relationship between root coverage procedures and buccal vestibular depth

Conditions: Shallow Vestibular Depth; Gingival Recession

Summary: in this comparative trial, 50 patients with shallow vestibules and type 1/2 recessions will be treated with either a vertically coronally advanced flap + connective tissue graft or a free gingival graft. at baseline, 3rd-month, 6th-month, and 12th-month visits, the following parameters will be evaluated: buccal vestibular depth, keratinized tissue height, gingival thickness, recession depth, recession width, probing depth, and clinical attachment level. keratinized tissue change, gingival thickness change, root coverage, clinical attachment gain, and complete root coverage will be calculated. the wound healing index, tissue appearance, patient expectations, aesthetics, and dentin hypersensitivity will be assessed at baseline and at the 6th week.

buccal vestibule depth was recorded using two different measurement methods. first, the distance between the cementoenamel junction and the deepest point of the vestibule sulcus was measured and recorded as vd1. then, the distance between the gingival margin and the base of the vestibule sulcus was measured and recorded as vd2.

Eligibility criteria:
inclusion criteria: * full-mouth plaque and bleeding scores \<15% * the presence of at least one recession type-1/2 recession and at least one recession with recession depth ≥ 2 mm * the presence of an identifiable cemento-enamel junction exclusion criteria: * vestibule depth \> 6mm * smoking \> 10 cigarettes per day * any contraindications for periodontal surgery * unstable endodontic conditions or presence of any restoration.